Takeda Pharmaceutical Co Aktie News & Pressemeldungen

Noticias de Eulerpool Takeda Pharmaceutical Co

22/10/2024, 20:42:52

Editas und Genevant: Partnerschaft für die Zukunft der Geneditierung

25/11/2024, 18:40:23

Neuer Hoffnungsträger im Kampf gegen Multiples Myelom: Blenreps Rückkehr

29/11/2024, 16:46:01

Innovationsschub in der IBD-Forschung: Takeda Kanada unterstützt bedeutende Studien

29/11/2024, 20:22:52

Takeda Canada stärkt innovative Forschung im Bereich entzündlicher Darmerkrankungen

3/12/2024, 20:35:53

Takeda und Keros: Partnerschaft zur globalen Vermarktung von Elritercept

Takeda Pharmaceutical Co Noticias de Acciones

Takeda Pharmaceutical Co es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Takeda Pharmaceutical Co.

17 de julio ·
SeekingAlpha
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector
15 de julio ·
SeekingAlpha
Astria: Betting On Navenibart In The Crowded HAE Arena
14 de julio ·
Yahoo
The No. 1 Key To Wealth, According To Wahei Takeda, the ‘Warren Buffett of Japan’
14 de julio ·
Yahoo
Takeda’s oral narcolepsy drug shines in two Phase III trials
14 de julio ·
Yahoo
Japanese Bonds Tumble as Fiscal Worries Mount Before Election
14 de julio ·
Yahoo
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
11 de julio ·
Yahoo
Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong
11 de julio ·
SeekingAlpha
Takeda: Positives And Negatives Offset Each Other
8 de julio ·
Yahoo
Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
7 de julio ·
SeekingAlpha
Wave Life Sciences: Speculative, But Promising

Takeda Pharmaceutical Co Noticias de la acción

Takeda Pharmaceutical Co publica regularmente en la página web de la empresa noticias relevantes para los inversores.

Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Suscripción por 2 € / mes

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan